Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2025)
Ultragenyx Pharmaceutical (RARE) reported Non Operating Income of -$934000.0 for Q4 2025, up 79.88% year-over-year from -$519224.4 in Q4 2024, and up 10.45% quarter-over-quarter from -$1.0 million in Q3 2025.
Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2025) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 13 years of Non Operating Income data on file, last reported at -$934000.0 in Q4 2025.
- Non Operating Income for Q4 2025 came in at -$934000.0, up 79.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (up 120.0% YoY), and the FY2025 annual result was $1.0 million, up 120.0% from the prior year.
- Non Operating Income improved to -$934000.0 in Q4 2025 per RARE's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $3.1 million in Q3 2024 and troughed at -$4.6 million in Q4 2024.
- A 5-year average of -$412650.0 and a median of -$557000.0 in 2021 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income plunged 1288.06% in 2022, then jumped 666.67% in 2023.
- A 5-year view of Non Operating Income shows it stood at -$410000.0 in 2021, then soared by 143.9% to $180000.0 in 2022, then jumped by 666.67% to $1.4 million in 2023, then plunged by 436.45% to -$4.6 million in 2024, then soared by 79.88% to -$934000.0 in 2025.
- Business Quant data shows RARE's Non Operating Income at -$934000.0 in Q4 2025, -$1.0 million in Q3 2025, and $2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -934,000.00 |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 837,000.00 |
| Dec 31, 2024 | -4.64 Mn |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.61 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | -699,000.00 |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | 308,000.00 |
| Dec 31, 2022 | 180,000.00 |
| Sep 30, 2022 | -1.11 Mn |
| Jun 30, 2022 | -930,000.00 |
| Mar 31, 2022 | 289,000.00 |
| Dec 31, 2021 | -410,000.00 |
| Sep 30, 2021 | -415,000.00 |
| Jun 30, 2021 | -67,000.00 |
| Mar 31, 2021 | -795,000.00 |